STOCK TITAN
  1. Home
  2. News
  3. AUTL

Autolus Therapeutics to report second quarter 2023 financial results and host conference call on August 3, 2023

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings

LONDON, July 18, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its second quarter 2023 financial results and operational highlights before open of US markets on Thursday, August 3, 2023.

Management will host a conference call and webcast at 8:30 am EDT/1:30 pm BST to discuss the company’s financial results and provide a general business update. Conference call participants should pre-register using this link to receive the dial-in numbers and a personal PIN, which are required to access the conference call.

A simultaneous audio webcast and replay will be accessible on the events section of Autolus’ website.

Contact:

Julia Wilson
+44 (0) 7818 430877
j.wilson@autolus.com

Susan A. Noonan
S.A. Noonan Communications
+1-917-513-5303
susan@sanoonan.com

Alexandra Deschner
+ +32-490-58-35-23
a.deschner@autolus.com


Stock AUTL logo
Autolus Therapeutics plc American Depositary Share

NASDAQ:AUTL

AUTL Rankings

#2358 Ranked by Market Cap
#2489 Ranked by Stock Gains
N/A Ranked by Dividends

AUTL Latest News

Apr 24, 2024
Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO
Apr 23, 2024
Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
Apr 2, 2024
Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Apr 1, 2024
Autolus Therapeutics Announces Changes to its Board of Directors
Mar 14, 2024
Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates

AUTL Stock Data

1.11B
91.18M
18.04%
53.51%
1.57%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
LONDON

About AUTL

autolus is a private biopharmaceutical company, focused on the development and commercialisation of engineered t-cell immunotherapy products with extreme efficacy in the treatment of life-threatening cancers. we are building a leading biotechnology company focussed on the development and commercialisation of engineered t-cell therapies for haematological and solid tumours. autolus has the ambition to be a leader of a revolution in medicine in which life-threatening diseases are treated by a patient’s own cells.